An interventional study of F&P Mask in Chronic Respiratory Conditions and Obstructive Sleep Apnea (OSA), sponsored by Fisher and Paykel Healthcare. Not yet recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Fisher and Paykel Healthcare · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Sleep Apnea, Obstructive by Fisher and Paykel Healthcare — 2 open to participants now, 2 under way, none of them phase 3. Sleep Apnea, Obstructive · Fisher and Paykel Healthcare.
Among the 63 studies in Sleep Apnea, Obstructive by Fisher and Paykel Healthcare, this one is the 14th largest by planned enrollment of the 60 interventional ones that give a count, is one of 2 that started in 2026, is one of 58 with no phase, and was the 63rd registered.
2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.
Browse Sleep Apnea, Obstructive studies →2 of the 63 studies in Sleep Apnea, Obstructive by Fisher and Paykel Healthcare are open now, in 1 country. Recruiting first, the newest first:
Fisher and Paykel Healthcare · Sites in United States
Ages 22+
By country, each count listing its studies:
Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 3 1 · Phase 4 1
First in 2006; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 45 is below the median of 52 across 1,474 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 34 across the 60 interventional studies, 110 across the 3 observational. Of the 60 that completed or were terminated, 27 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fisher and Paykel Healthcare is the lead sponsor of 86 studies on the registry; 16 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
2 of the studies in Sleep Apnea, Obstructive by Fisher and Paykel Healthcare that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07826429Fisher and Paykel HealthcareEvaluation of the F&P Mask, US, 2026 | 2027-04-21 |
| NCT07847814Fisher and Paykel HealthcareEvaluation of F&P Mask, US, 2026 | 2027-05-14 |
Add all 2 to your calendar (.ics) → With an account.
Among the 63 studies in Sleep Apnea, Obstructive by Fisher and Paykel Healthcare, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical investigation is designed to validate and confirm the overall performance, safety, usability, reliability, and acceptability of the F\&P mask in a home environment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-arm, non-randomised, open-label
Device: F&P Mask
PAP/NIV Therapy Mask
Therapeutic Efficacy
Determined by Apnea-Hypopnea Index (AHI) recorded on PAP therapy machines after 14 days of use. The Apnea-Hypopnea index (AHI) is the sum of the apneas and hypopneas divided by the hours of sleep. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and \>= 30/h = severe AHI is measured by dividing the total number of recorded apneas (complete breathing stops) and hypopneas (shallow breathing episodes) by the total number of hours a person slept during an overnight sleep study or using a PAP device. Higher AHI values represent worse outcomes. There is no maximum theoretical index score.
Time frame: Baseline and 14±5 days
Epworth Sleepiness Scale
All relevant time points used in the calculation in the Time Frame (e.g., baseline and 14±5 days). Note: change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 14±5 days minus value at baseline). Change between two time points is reported. Scale range: 0 (minimum score) to 24 (maximum score) (higher scores represent worse outcomes)
Time frame: 14±5 days
Patient and Clinical Global Impression (PGI/CGI)
Determined by Patient Global Impression (PGI) and Clinical Global Impression (CGI) assessments completed at baseline and Day 14. Baseline symptom severity is assessed using a 6-point scale (1 = No symptoms to 6 = Very severe symptoms). Change from baseline is assessed using a 7-point scale (1 = Very much better to 7 = Very much worse; 4 = No change). Higher severity scores indicate worse symptoms. For change assessments, lower scores indicate improvement and higher scores indicate worsening. PGI is completed by the patient and CGI is completed by the investigator/clinician.
Time frame: Baseline and 14±5 days
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for May 2027, 6 months later.
Of 116 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 6 months is below that.
Counting every sponsor, half of 624 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fisher and Paykel Healthcare →